Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Tanner, Matthew J ^a   Welliver Jr , R Charles ^b,c   Chen, Mengqian ^a   Shtutman, Michael ^a   Godoy, Alejandro ^d   Smith, Gary ^d   Mian, Badar M ^b,c   Buttyan, Ralph ^a,b  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c STRATTON VA MEDICAL CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; MITOGEN ACTIVATED PROTEIN KINASE; SONIC HEDGEHOG PROTEIN;

ARTICLE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; PARACRINE SIGNALING; PROSTATE CANCER; STROMA CELL; UPREGULATION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ERINACEIDAE;

ANDROGENS; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MALE; PARACRINE COMMUNICATION; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS;

EID: 79251558837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016027     Document Type: Article

References (35)

1. Imperato-McGinley J, Zhu YS (2002) Androgens and male physiology the syndrome of 5alpha reductase-2 deficiency. Mol Cell Endocrinol 198: 51-59.
2. Sultan C, Lumbroso S, Poujol N, Belon C, Boudon C, et al. (1993) Mutations of androgen receptor gene in androgen insensitivity syndromes. J Steroid Biochem Mol Biol 46: 519-530.
3. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA (2009) Chemoprevention of prostate cancer. J Urol 182: 499-507.
4. Miyamoto H, Messing EM, Chang C (2004) Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61: 332-353.
5. Dehm SM, Tindall DJ (2006) Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99: 333-344.
6. Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, et al. (2001) Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 92: 322-328.
7. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, et al. (2004) Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinol 145: 3913-3924.
8. Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, et al. (2007) Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer 6: 39.
9. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S, et al. (2009) Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28: 2051-2063.
10. Liu AY, Corey E, Vessella RL, Lange PH, True LD, et al. (1997) Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate 30: 145-153.
11. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, et al. (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24: 3847-3852.
12. Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bo TH, et al. (2007) ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 30: 19-32.
13. Hu P, Greenwood CM, Beyene J (2007) Integrative analysis of gene expression data including an assessment of pathway enrichment for predicting prostate cancer. Cancer Inform 2: 289-300.
14. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, et al. (2009) Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 2: 48.
15. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW (1991) Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51: 3753-3761.
16. Cunha GR, Hayward SW, Wang YZ (2002) Role of stroma in carcinogenesis of the prostate. Differentiation 70: 473-485.
17. Cunha GR, Hayward SW, Wang YZ, Ricke WA (2003) Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 107: 1-10.
18. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, et al. (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92: 221-236.
19. Chung LW, Baseman A, Assikis V, Zhau HE (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10-20.
20. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, et al. (1999) A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 20: 1185-1192.
21. Draghici S, Khatri P, Tarca AL, Amin K, Done A, et al. (2007) A systems biology approach for pathway level analysis. Genome Res 17: 1537-1545.
22. Sar M, Lubahn DB, French FS, Wilson EM (1990) Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinol 127: 3180-3186.
23. Iwamura M, Abrahamsson PA, Benning CM, Cockett AT, di Sant'Agnese PA (1994) Androgen receptor immunostaining and its tissue distribution in formalinfixed, paraffin-embedded sections after microwave treatment. J Histochem Cytochem 42: 783-788.
24. Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, et al. (1996) Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 2: 889-895.
25. Price DT, Rudner X, Michelotti GA, Schwinn DA (2000) Immortalization of a human prostate stromal cell line using a recombinant retroviral approach. J Urol 164: 2145-2150.
26. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, et al. (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15: 39-47.
27. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, et al. (1997) Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 126: 59-73.
28. Jiang M, Ma Y, Chen C, Fu X, Yang S, et al. (2009) Androgen-responsive gene database: integrated knowledge on androgen-responsive genes. Mol Endocrinol 23: 1927-1933.
29. Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, et al. (2009) Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase. Prostate 69: 949-955.
30. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, et al. (2009) The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Res 69: 7111-7120.
31. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, et al. (2008) Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 27: 7118-7130.
32. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, et al. (2004) Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64: 7156-7168.
33. Cano P, Godoy A, Escamilla R, Dhir R, Onate SA (2007) Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Res 67: 511-519.
34. Mechlin CW, Tanner MJ, Chen M, Buttyan R, Levin RM, et al. (2010) Gli2 expression and human bladder transitional carcinoma cell invasiveness. J Urol 184: 344-351.
35. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, et al. (2009) Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 8: 149-157.